BCL2 and B-cell chronic lymphocytic leukemia: As we and others previously reported [11, 25, 26], BH3 mimetics targeting BCL2 could trigger MOMP in permeabilized CLL cells, but a high concentration of the drug was required (IC50 > 1 μM; Fig. 1A).